From July 28 to 30, 2026, ADLM (formerly AACC Annual Scientific Meeting & Clinical Lab Expo) grandly kicked off at the Anaheim Convention Center in California. Hangzhou Biotest Biotech Co., Ltd. made a prominent appearance at this benchmark North American clinical laboratory medicine exhibition alongside its U.S. subsidiary ADVIN BIOTECH. Showcasing core technologies, a comprehensive product portfolio and mature overseas deployment, the company fully demonstrated its innovative strengths in the in vitro diagnostics (IVD) sector and momentum for global expansion.

 

Cutting-Edge Product Debut with Fully Upgraded Product Line up

The booth featured the upgraded FluidicNow™ Microfluidic Immunofluorescence Analysis System as a highlight. Powered by self-developed high-sensitivity sensing technology, it enables rapid detection of multiple biomarkers and caters to diverse scenarios including hospital emergency departments, primary care clinics and  POCT. Boasting outstanding detection stability and user-friendly operation, the platform drew extensive attention from professional overseas visitors.

 

Also on display were innovative oral fluid drug test and the DiagPal^TM series Lateral Flow Readers. With reliable testing performance, high innovation and full compliance with overseas application standards, these products attracted numerous North American scholars, clients and industry peers to stop for in-depth discussions. Product performance, on-site implementation and partnership models were thoroughly communicated, yielding multiple potential cooperation leads.

 

Deep Cultivation in North America, Joint Efforts for Win-Win Cooperation

Hosted at a core exhibition hub on the U.S. West Coast and a biomedical industry cluster in Southern California, ADLM brings together IVD enterprises, research experts and global procurement specialists worldwide. It serves as a pivotal platform for industry players to tap into the North American market and facilitate cross-border technical and commercial collaboration.
By engaging directly with the international marketplace and benchmarking against industry cutting-edge standards, Biotest gained deeper insights into the development trends of the North American IVD sector, while effectively boosting its regional brand recognition and industry reputation across North America.

 

Rooted in Global Overseas Markets, Forging a Far-Reaching Global Brand

Participation in this exhibition marks a key milestone for Biotest Biotech and Advin Biotech to deepen their North American footprint and align with international advanced industry standards. Amid transformative shifts within the IVD industry, the company will remain laser-focused on core in vitro diagnostics segments. Guided by real market demands, Biotest will keep refining premium diagnostic products and integrated solutions, advance cross-border communication and partnerships, expand global sales channels, and steadily elevate its worldwide brand competitiveness.